USSTOCK.TODAY
Pre-Market
Log in Sign up

Viking Therapeutics seeks market expansion by starting Phase 3 clinical trials for oral VK2735

The Motley Fool +1 · ·by G4L

VKTX
VKTX Viking Therapeutics Inc
$27.58 -3.02%
View chart & analysis →
  1. 1Viking Therapeutics is currently conducting four Phase 3 clinical trials for its core drug, VK2735.
  2. 2This quarter, it launched Sunrise-1 and Sunrise-2, which are 68-week oral VK2735 clinical trials.
  3. 3A 20% rate of patients discontinuing treatment due to side effects was previously recorded among Phase 2 clinical patients.

So what's the key point?

Viking Therapeutics has started Phase 3 clinical trials for VK2735, an oral medication. In the previous stage, 20% of patients stopped treatment due to side effects.

Source The Motley Fool +1 · View original ↗

Related 3-line summaries

Eli Lilly raises revenue guidance and Viking Therapeutics competes in obesity treatment market The Motley Fool +1 · yesterdayEli Lilly widens market cap gap with Novo Nordisk in obesity treatment competition The Motley Fool +7 · 3d agoViking Therapeutics shares fall approximately 23% below capital increase issue price The Motley Fool +1 · Nov 4
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news